UPDATE: Morgan Stanley Initiates Synageva Biopharma with Buy, $76 PT

27% profits every 20 days?

This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.

Morgan Stanley initiates its coverage on Synageva Biopharma (NASDAQ: GEVA) with a Buy rating and a price target of $76 as it sees potential on an early but appealing orphan drug company. Morgan Stanley notes, "Synageva is focused on developing drugs for ultra-orphan diseases, an attractive area due to the streamlined development paths, more sustained pricing power (thus far), and higher operating margins. We are initiating OW as we believe the early proof of concept data for SBC-102 (see below) and the company's planned approach to commercialization could allow them to follow this successful ultra-orphan path."GEVA closed at $24.40 on Thursday.

27% profits every 20 days?

ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!